

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A human monoclonal antibody that binds to Platelet Derived Growth Factor D (PDGFD) and comprises a heavy chain amino acid sequence comprising SEQ ID NO: 48.
2. (previously presented) The antibody of Claim 1, further comprising a light chain amino acid sequence comprising SEQ ID NO:49.
- 3-21. (canceled)
22. (previously presented) A human monoclonal antibody or antigen-binding portion thereof that specifically binds to Platelet Derived Growth Factor D (PDGFD) and is encoded by a human V_H1-8 family gene and a J_H6B family gene.
23. (currently amended) The human monoclonal antibody or antigen-binding portion thereof of Claim 22, wherein said monoclonal antibody comprises a heavy chain polypeptide comprising having the sequence of SEQ ID NO:48 and a light chain polypeptide comprising having the sequence of SEQ ID NO:49.
24. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion comprises a heavy chain CDR1 region comprising having the amino acid sequence residues 26-35 of SEQ ID NO:48, GYTFTSYDIN.
25. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion comprises a heavy chain CDR2 region comprising having the amino acid sequence residues 51-65 of SEQ ID NO:48, INPNSGNTDYAQKFQ.
26. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion comprises a heavy chain CDR3 region comprising having the amino acid sequence residues 99-114 of SEQ ID NO:48, GFGYSYNDYDYYGMDV.

27. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion thereof comprises a light chain CDR1 region comprising having the amino acid sequence residues 24-35 of SEQ ID NO:49, RASQSVSSSYLA.
28. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion thereof comprises a light chain CDR2 region comprising having the amino acid sequence residues 51-57 of SEQ ID NO:49, ATSSRAT.
29. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion thereof comprises a light chain CDR3 region comprising having the amino acid sequence residues 90-98 of SEQ ID NO:49, QQYGSSPCS.
30. (previously presented) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion thereof further comprises a sequence encoded by a human D5-18 family gene.
31. (currently amended) The human monoclonal antibody or antigen binding portion thereof of Claim 22, wherein said monoclonal antibody or antigen binding portion thereof further comprises a detectable marker.
32. (previously presented) A human monoclonal antibody that binds to Platelet Derived Growth Factor D (PDGFD) and is derived from a human V_H1-8 family gene and a J_H6B family gene.
33. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a heavy chain polypeptide comprising having the sequence of SEQ ID NO:48 and a light chain polypeptide comprising having the sequence of SEQ ID NO:49.
34. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a heavy chain CDR1 region comprising having the amino acid sequence residues 26-35 of SEQ ID NO:48, GYTFTSYDIN.

35. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a heavy chain CDR2 region comprising ~~having~~ the amino acid sequence residues 51-65 of SEQ ID NO:48, INPNSGNTDYAQKFQ.
36. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a heavy chain CDR3 region comprising ~~having~~ the amino acid sequence residues 99-114 of SEQ ID NO:48, GFGYSYNYDYYYGMDV.
37. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a light chain CDR1 region comprising ~~having~~ the amino acid sequence residues 24-35 of SEQ ID NO:49, RASQSVSSSYLA.
38. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a light chain CDR2 region comprising ~~having~~ the amino acid sequence residues 51-57 of SEQ ID NO:49, ATSSRAT.
39. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody comprises a light chain CDR3 region comprising ~~having~~ the amino acid sequence residues 90-98 of SEQ ID NO:49, QQYGSSPCS.
40. (previously presented) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody further comprises a sequence derived from a human D5-18 family gene.
41. (currently amended) The human monoclonal antibody of Claim 32, wherein said monoclonal antibody further comprises a detectable marker.
42. (previously presented) A composition comprising a human monoclonal antibody or antigen-binding portion thereof that specifically binds to Platelet Derived Growth Factor D (PDGFD) and is encoded by a human V_H1-8 family gene and a J_H6B family gene in association with a pharmaceutically acceptable carrier.
43. (previously presented) The composition of Claim 42, wherein said human monoclonal antibody or antigen-binding portion thereof further comprises a sequence encoded by a human D5-18 family gene.
44. (currently amended) The composition of Claim 42, wherein said human monoclonal antibody or antigen-binding portion thereof comprises a heavy chain polypeptide

Applicants: Corvalan et al.
U.S.S.N.: 10/041,860

comprising ~~having~~ the sequence of SEQ ID NO:48 and a light chain polypeptide
comprising ~~having~~ the sequence of SEQ ID NO:49.

45. (currently amended) The composition of Claim 42, wherein said human monoclonal antibody or antigen-binding portion thereof further comprises a detectable marker.